— Diebold Nixdorf (NYSE: DBD) reported a third-quarter 2019 adjusted loss of $0.06 per share versus a profit of $0.24 per share expected.
— Total net sales declined by 4% to $1.08 billion versus $1.1 billion expected. The results were impacted by persistent currency headwinds and certain slow economic activity, notably in Europe, which is hurting customer demand for Retail solutions.
— Sales from Eurasia Banking declined by 7% while that from the Americas Banking increased by 6%. Total retail sales fell by 11%.
— Looking ahead into the full year 2019, the company lowered its total revenue outlook to about $4.4 billion from the previous estimate of about $4.5 billion.
— Adjusted EBITDA is now expected to be in the range of $400 million to $410 million compared to the prior forecast range of $400 million to $420 million.
— Net cash provided by operating activities is now predicted to be in the $120 million to $150 million range, up from the earlier forecast of about $100 million.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
